156 related articles for article (PubMed ID: 26360058)
61. MAPK-ERK is a central pathway in T-cell acute lymphoblastic leukemia that drives steroid resistance.
van der Zwet JCG; Buijs-Gladdines JGCAM; Cordo' V; Debets DO; Smits WK; Chen Z; Dylus J; Zaman GJR; Altelaar M; Oshima K; Bornhauser B; Bourquin JP; Cools J; Ferrando AA; Vormoor J; Pieters R; Vormoor B; Meijerink JPP
Leukemia; 2021 Dec; 35(12):3394-3405. PubMed ID: 34007050
[TBL] [Abstract][Full Text] [Related]
62. Activated EGFR promotes the survival of B-lineage acute leukemia in the absence of stromal cells.
Spengeman JD; Green TD; McCubrey JA; Bertrand FE
Cell Cycle; 2005 Mar; 4(3):483-7. PubMed ID: 15701973
[TBL] [Abstract][Full Text] [Related]
63. Trametinib Drives T-cell-Dependent Control of KRAS-Mutated Tumors by Inhibiting Pathological Myelopoiesis.
Allegrezza MJ; Rutkowski MR; Stephen TL; Svoronos N; Perales-Puchalt A; Nguyen JM; Payne KK; Singhal S; Eruslanov EB; Tchou J; Conejo-Garcia JR
Cancer Res; 2016 Nov; 76(21):6253-6265. PubMed ID: 27803104
[TBL] [Abstract][Full Text] [Related]
64. CREB knockdown inhibits growth and induces apoptosis in human pre-B acute lymphoblastic leukemia cells through inhibition of prosurvival signals.
Shabestari RM; Safa M; Alikarami F; Banan M; Kazemi A
Biomed Pharmacother; 2017 Mar; 87():274-279. PubMed ID: 28063408
[TBL] [Abstract][Full Text] [Related]
65. Mer receptor tyrosine kinase is a novel therapeutic target in pediatric B-cell acute lymphoblastic leukemia.
Linger RM; DeRyckere D; Brandão L; Sawczyn KK; Jacobsen KM; Liang X; Keating AK; Graham DK
Blood; 2009 Sep; 114(13):2678-87. PubMed ID: 19643988
[TBL] [Abstract][Full Text] [Related]
66. Oncogene-independent BCR-like signaling adaptation confers drug resistance in Ph-like ALL.
Hurtz C; Wertheim GB; Loftus JP; Blumenthal D; Lehman A; Li Y; Bagashev A; Manning B; Cummins KD; Burkhardt JK; Perl AE; Carroll M; Tasian SK
J Clin Invest; 2020 Jul; 130(7):3637-3653. PubMed ID: 32191635
[TBL] [Abstract][Full Text] [Related]
67. The impact of MCCK1, an inhibitor of IKBKE kinase, on acute B lymphocyte leukemia cells.
Wen S; Zhao P; Chen S; Deng B; Fang Q; Wang J
Math Biosci Eng; 2024 Mar; 21(4):5164-5180. PubMed ID: 38872531
[TBL] [Abstract][Full Text] [Related]
68. The histone demethylase PHF8 promotes adult acute lymphoblastic leukemia through interaction with the MEK/ERK signaling pathway.
Fu Y; Yang Y; Wang X; Yin X; Zhou M; Wang S; Yang L; Huang T; Xu M; Chen C
Biochem Biophys Res Commun; 2018 Feb; 496(3):981-987. PubMed ID: 29330049
[TBL] [Abstract][Full Text] [Related]
69. Ex vivo treatment of patient biopsies as a novel method to assess colorectal tumour response to the MEK1/2 inhibitor, Selumetinib.
Novo SM; Wedge SR; Stark LA
Sci Rep; 2017 Sep; 7(1):12020. PubMed ID: 28931905
[TBL] [Abstract][Full Text] [Related]
70. Interleukin-18 produced by bone marrow-derived stromal cells supports T-cell acute leukaemia progression.
Uzan B; Poglio S; Gerby B; Wu CL; Gross J; Armstrong F; Calvo J; Cahu X; Deswarte C; Dumont F; Passaro D; Besnard-Guérin C; Leblanc T; Baruchel A; Landman-Parker J; Ballerini P; Baud V; Ghysdael J; Baleydier F; Porteu F; Pflumio F
EMBO Mol Med; 2014 Jun; 6(6):821-34. PubMed ID: 24778454
[TBL] [Abstract][Full Text] [Related]
71. Viable bone marrow stromal cells are required for the in vitro survival of B-cell precursor acute lymphoblastic leukemic cells.
Ashley DM; Bol SJ; Kannourakis G
Leuk Res; 1995 Feb; 19(2):113-20. PubMed ID: 7869739
[TBL] [Abstract][Full Text] [Related]
72. High-Throughput Flow Cytometry Identifies Small-Molecule Inhibitors for Drug Repurposing in T-ALL.
Perez DR; Nickl CK; Waller A; Delgado-Martin C; Woods T; Sharma ND; Hermiston ML; Loh ML; Hunger SP; Winter SS; Chigaev A; Edwards B; Sklar LA; Matlawska-Wasowska K
SLAS Discov; 2018 Aug; 23(7):732-741. PubMed ID: 29746793
[TBL] [Abstract][Full Text] [Related]
73. MEK inhibition as a strategy for targeting residual breast cancer cells with low DUSP4 expression.
Rottenberg S; Jonkers J
Breast Cancer Res; 2012 Nov; 14(6):324. PubMed ID: 23127286
[TBL] [Abstract][Full Text] [Related]
74. Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia.
Degryse S; de Bock CE; Demeyer S; Govaerts I; Bornschein S; Verbeke D; Jacobs K; Binos S; Skerrett-Byrne DA; Murray HC; Verrills NM; Van Vlierberghe P; Cools J; Dun MD
Leukemia; 2018 Mar; 32(3):788-800. PubMed ID: 28852199
[TBL] [Abstract][Full Text] [Related]
75. Predicting MEK Inhibitor Response in Lung Cancer: A Proper Signature Is Required.
Xue Y; Lito P
Clin Cancer Res; 2017 Mar; 23(6):1365-1367. PubMed ID: 27923842
[TBL] [Abstract][Full Text] [Related]
76. Disruption of E627 and R683 interaction is responsible for B-cell acute lymphoblastic leukemia caused by JAK2 R683G(S) mutations.
Wu QY; Guo HY; Li F; Li ZY; Zeng LY; Xu KL
Leuk Lymphoma; 2013 Dec; 54(12):2693-700. PubMed ID: 23452118
[TBL] [Abstract][Full Text] [Related]
77. Transient rRNA synthesis inhibition with CX-5461 is sufficient to elicit growth arrest and cell death in acute lymphoblastic leukemia cells.
Negi SS; Brown P
Oncotarget; 2015 Oct; 6(33):34846-58. PubMed ID: 26472108
[TBL] [Abstract][Full Text] [Related]
78. ERK1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia.
Gregorj C; Ricciardi MR; Petrucci MT; Scerpa MC; De Cave F; Fazi P; Vignetti M; Vitale A; Mancini M; Cimino G; Palmieri S; Di Raimondo F; Specchia G; Fabbiano F; Cantore N; Mosna F; Camera A; Luppi M; Annino L; Miraglia E; Fioritoni G; Ronco F; Meloni G; Mandelli F; Andreeff M; Milella M; Foà R; Tafuri A;
Blood; 2007 Jun; 109(12):5473-6. PubMed ID: 17351113
[TBL] [Abstract][Full Text] [Related]
79. Inhibition of ERK 1/2 kinases prevents tendon matrix breakdown.
Blache U; Wunderli SL; Hussien AA; Stauber T; Flückiger G; Bollhalder M; Niederöst B; Fucentese SF; Snedeker JG
Sci Rep; 2021 Mar; 11(1):6838. PubMed ID: 33767224
[TBL] [Abstract][Full Text] [Related]
80. Kinase inhibitors: an allosteric add-on.
Foda ZH; Seeliger MA
Nat Chem Biol; 2014 Oct; 10(10):796-7. PubMed ID: 25195010
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
